Physician profile
Mark Corso
NPI 1578635090
$1,643.05
in general payments reported to CMS, 2019-2025
22 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $31.53 · 2021: $147 · 2022: $169 · 2023: $178 · 2024: $645 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.98 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.02 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $126.44 | 2019-2025 | |
| Boston Scientific Corporation | $123.91 | 2021-2024 | Spyglass |
| E.R. Squibb & Sons, L.L.C. | $120.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.88 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $86.31 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Celgene Corporation | $84.91 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $65.44 | 2020-2023 | Sucraid |
| Gilead Sciences, INC. | $48.77 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.36 | 2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $41.04 | 2019-2024 | Clenpiq |
| Phathom Pharmaceuticals, INC. | $31.45 | 2025 | Voquezna |
| Olympus America INC. | $29.18 | 2019 | |
| Madrigal Pharmaceuticals | $26.45 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $24.34 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $24.21 | 2022 | |
| Ardelyx, INC. | $19.84 | 2025 | Ibsrela |
| Lilly USA, LLC | $19.55 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $18.50 | 2023 | Sutab |
| Shionogi INC | $17.08 | 2019 | |
| Sandoz INC. | $16.68 | 2024 | Hyrimoz |
| Micro-Tech Endoscopy USA, INC. | $6.69 | 2024 | Dilation Balloons |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Corso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.